Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% on Insider Selling

Denali Therapeutics Inc. (NASDAQ:DNLI) shares traded down 4.1% on Monday following insider selling activity. The stock traded as low as $20.25 and last traded at $20.39. 209,130 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 479,181 shares. The stock had previously closed at $21.26.

Specifically, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analyst Ratings Changes

A number of analysts have recently commented on DNLI shares. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group lifted their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Monday, December 16th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.40.

Denali Therapeutics Trading Down 6.8 %

The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -7.18 and a beta of 1.39. The firm’s 50-day moving average is $24.46 and its two-hundred day moving average is $24.89.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm posted ($0.72) earnings per share. On average, analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNLI. CWM LLC raised its position in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the last quarter. Quest Partners LLC purchased a new position in Denali Therapeutics in the 3rd quarter worth approximately $73,000. Assetmark Inc. lifted its stake in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after purchasing an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $194,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.